vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and DIODES INC (DIOD). Click either name above to swap in a different company.
DIODES INC is the larger business by last-quarter revenue ($391.6M vs $284.0M, roughly 1.4× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 2.6%, a 93.7% gap on every dollar of revenue. On growth, DIODES INC posted the faster year-over-year revenue change (15.4% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 13.9%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Diodes Incorporated is a global semiconductor manufacturer that designs, produces and supplies discrete, analog and mixed-signal semiconductor products. Its solutions serve key end markets including automotive, industrial, consumer electronics, personal computing and communications infrastructure, with a worldwide customer base.
ACAD vs DIOD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $391.6M |
| Net Profit | $273.6M | $10.2M |
| Gross Margin | 90.8% | 31.1% |
| Operating Margin | 6.1% | 3.4% |
| Net Margin | 96.3% | 2.6% |
| Revenue YoY | 9.4% | 15.4% |
| Net Profit YoY | 90.3% | 23.8% |
| EPS (diluted) | $1.61 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $391.6M | ||
| Q3 25 | $278.6M | $392.2M | ||
| Q2 25 | $264.6M | $366.2M | ||
| Q1 25 | $244.3M | $332.1M | ||
| Q4 24 | $259.6M | $339.3M | ||
| Q3 24 | $250.4M | $350.1M | ||
| Q2 24 | $242.0M | $319.8M | ||
| Q1 24 | $205.8M | $302.0M |
| Q4 25 | $273.6M | $10.2M | ||
| Q3 25 | $71.8M | $14.3M | ||
| Q2 25 | $26.7M | $46.1M | ||
| Q1 25 | $19.0M | $-4.4M | ||
| Q4 24 | $143.7M | $8.2M | ||
| Q3 24 | $32.8M | $13.7M | ||
| Q2 24 | $33.4M | $8.0M | ||
| Q1 24 | $16.6M | $14.0M |
| Q4 25 | 90.8% | 31.1% | ||
| Q3 25 | 92.2% | 30.7% | ||
| Q2 25 | 92.2% | 31.5% | ||
| Q1 25 | 91.7% | 31.5% | ||
| Q4 24 | 91.6% | 32.7% | ||
| Q3 24 | 92.5% | 33.7% | ||
| Q2 24 | 92.5% | 33.6% | ||
| Q1 24 | 88.8% | 33.0% |
| Q4 25 | 6.1% | 3.4% | ||
| Q3 25 | 12.8% | 3.0% | ||
| Q2 25 | 12.2% | 2.6% | ||
| Q1 25 | 7.9% | 0.4% | ||
| Q4 24 | 59.1% | 3.5% | ||
| Q3 24 | 12.6% | 6.2% | ||
| Q2 24 | 12.6% | 1.2% | ||
| Q1 24 | 7.4% | 4.3% |
| Q4 25 | 96.3% | 2.6% | ||
| Q3 25 | 25.8% | 3.6% | ||
| Q2 25 | 10.1% | 12.6% | ||
| Q1 25 | 7.8% | -1.3% | ||
| Q4 24 | 55.4% | 2.4% | ||
| Q3 24 | 13.1% | 3.9% | ||
| Q2 24 | 13.8% | 2.5% | ||
| Q1 24 | 8.0% | 4.6% |
| Q4 25 | $1.61 | $0.23 | ||
| Q3 25 | $0.42 | $0.31 | ||
| Q2 25 | $0.16 | $0.99 | ||
| Q1 25 | $0.11 | $-0.10 | ||
| Q4 24 | $0.86 | $0.18 | ||
| Q3 24 | $0.20 | $0.30 | ||
| Q2 24 | $0.20 | $0.17 | ||
| Q1 24 | $0.10 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $377.0M |
| Total DebtLower is stronger | — | $25.7M |
| Stockholders' EquityBook value | $1.2B | $1.9B |
| Total Assets | $1.6B | $2.4B |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $377.0M | ||
| Q3 25 | $258.0M | $386.4M | ||
| Q2 25 | $253.6M | $327.3M | ||
| Q1 25 | $217.7M | $343.9M | ||
| Q4 24 | $319.6M | $316.1M | ||
| Q3 24 | $155.1M | $319.3M | ||
| Q2 24 | $177.1M | $273.9M | ||
| Q1 24 | $204.7M | $276.0M |
| Q4 25 | — | $25.7M | ||
| Q3 25 | — | $24.9M | ||
| Q2 25 | — | $26.4M | ||
| Q1 25 | — | $20.5M | ||
| Q4 24 | — | $20.7M | ||
| Q3 24 | — | $22.2M | ||
| Q2 24 | — | $20.3M | ||
| Q1 24 | — | $20.9M |
| Q4 25 | $1.2B | $1.9B | ||
| Q3 25 | $917.3M | $1.9B | ||
| Q2 25 | $822.4M | $1.9B | ||
| Q1 25 | $765.2M | $1.8B | ||
| Q4 24 | $732.8M | $1.8B | ||
| Q3 24 | $577.2M | $1.8B | ||
| Q2 24 | $516.7M | $1.8B | ||
| Q1 24 | $464.0M | $1.7B |
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.3B | $2.5B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.1B | $2.4B | ||
| Q4 24 | $1.2B | $2.4B | ||
| Q3 24 | $976.9M | $2.4B | ||
| Q2 24 | $914.1M | $2.4B | ||
| Q1 24 | $855.1M | $2.4B |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 0.01× | ||
| Q1 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $38.1M |
| Free Cash FlowOCF − Capex | — | $12.4M |
| FCF MarginFCF / Revenue | — | 3.2% |
| Capex IntensityCapex / Revenue | — | 6.6% |
| Cash ConversionOCF / Net Profit | -0.18× | 3.74× |
| TTM Free Cash FlowTrailing 4 quarters | — | $137.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $38.1M | ||
| Q3 25 | $74.3M | $79.1M | ||
| Q2 25 | $64.0M | $41.5M | ||
| Q1 25 | $20.3M | $56.7M | ||
| Q4 24 | $40.4M | $81.8M | ||
| Q3 24 | $63.2M | $54.4M | ||
| Q2 24 | $25.0M | $14.4M | ||
| Q1 24 | $29.1M | $-31.1M |
| Q4 25 | — | $12.4M | ||
| Q3 25 | $73.9M | $62.8M | ||
| Q2 25 | — | $21.1M | ||
| Q1 25 | — | $40.8M | ||
| Q4 24 | — | $62.1M | ||
| Q3 24 | $63.2M | $39.4M | ||
| Q2 24 | — | $-3.5M | ||
| Q1 24 | — | $-51.5M |
| Q4 25 | — | 3.2% | ||
| Q3 25 | 26.5% | 16.0% | ||
| Q2 25 | — | 5.8% | ||
| Q1 25 | — | 12.3% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | 25.2% | 11.2% | ||
| Q2 24 | — | -1.1% | ||
| Q1 24 | — | -17.1% |
| Q4 25 | — | 6.6% | ||
| Q3 25 | 0.1% | 4.2% | ||
| Q2 25 | — | 5.6% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | 0.0% | 4.3% | ||
| Q2 24 | — | 5.6% | ||
| Q1 24 | — | 6.7% |
| Q4 25 | -0.18× | 3.74× | ||
| Q3 25 | 1.03× | 5.54× | ||
| Q2 25 | 2.40× | 0.90× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | 9.93× | ||
| Q3 24 | 1.93× | 3.95× | ||
| Q2 24 | 0.75× | 1.80× | ||
| Q1 24 | 1.76× | -2.22× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
DIOD
| Distributor | $253.1M | 65% |
| Direct Sales | $138.5M | 35% |
